t(8;9)(q24;p13) ?/MYC
2013-10-01 Jean-Loup Huret   Affiliation1.Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France
Clinics and Pathology
Disease
B-cell acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL)
Phenotype stem cell origin
There were 5 cases of ALL (L3-ALLs and CD10+ ALLs in 2 cases each), 11 cases of diffuse large B-cell lymphoma (DLBCL), 7 cases of unclassifiable B-cell lymphoma, one case of follicular lymphoma, and one case of diffuse mixed small and large cell lymphoma (Levine et al., 1989; Nacheva et al., 1993; Dunphy et al., 2003; DAchille et al., 2006; Bertrand et al., 2007; Le Gouill et al., 2007; Christie et al., 2008; Johnson et al., 2009; Subramaniyam et al., 2011).
Epidemiology
Twenty five cases are available. There were 12 male and 13 female patients, median age was 63 years (range 42-90 years). In a review of NHLs with a t(14;18)(q32;q21), the incidence of MYC translocations was 5%, and the incidence of t(8;9)(q24;p13) was 1% (Johansson et al., 1995).

Meta-analysis of survival in patients with t(8;9)(q24;p13).
Prognosis
Median survival was 4 months (see figure). However, patients with an ALL died at 1, 1, 1.5, and 1.5 months. Median survival of patients with NHL was 6 months, and 3 out of 19 NHL patients were still alive 5 years after diagnosis (16%).
Genes Involved and Proteins
Note
Breakpoints occurred close to MYC on chromosome 8 and close to: ZBTB5, ZCCHC7, and PAX5 on chromosome 9 (Bertrand et al., 2007; Le Gouill et al., 2007; Johnson et al., 2009).
- ZBTB5 is a POZ domain Krüppel-like zinc finger transcription repressor. ZBTB5 interacted with co-repressor-histone deacetylase complexes such as BCOR, NCOR1, and NCOR2 (SMRT), resulting in deacetylation of histones Ac-H3 and Ac-H4, and transcriptional repression of CDKN1A (p21) (Koh et al., 2009).
- ZCCHC7 is the equivalent of the yeast AIR1. In yeast, a number of unwanted RNA transcripts are first recognized by the nuclear exosome cofactor Trf4/5p-Air1/2p-Mtr4p polyadenylation (TRAMP) complex before subsequent nuclear-exosome-mediated degradation. TRAMP facilitates pre-mRNA splicing (Kong et al., 2013).
- PAX5 is a lineage-specific transcription factor; recognizes the concensus recognition sequence GNCCANTGAAGCGTGAC, where N is any nucleotide. Involved in B-cell differentiation. Entry of common lymphoid progenitors into the B cell lineage depends on E2A, EBF1, and PAX5; activates B-cell specific genes and represses genes involved in other lineage commitments. Activates the surface cell receptor CD19 and represses FLT3. PAX5 physically interacts with the RAG1/RAG2 complex, and removes the inhibitory signal of the lysine-9-methylated histone H3, and induces V-to-DJ rearrangements. Genes repressed by PAX5 expression in early B cells are restored in their function in mature B cells and plasma cells, and PAX5 repressed (Fuxa et al., 2004; Johnson et al., 2004; Zhang et al., 2006; Cobaleda et al., 2007).
- ZBTB5 is a POZ domain Krüppel-like zinc finger transcription repressor. ZBTB5 interacted with co-repressor-histone deacetylase complexes such as BCOR, NCOR1, and NCOR2 (SMRT), resulting in deacetylation of histones Ac-H3 and Ac-H4, and transcriptional repression of CDKN1A (p21) (Koh et al., 2009).
- ZCCHC7 is the equivalent of the yeast AIR1. In yeast, a number of unwanted RNA transcripts are first recognized by the nuclear exosome cofactor Trf4/5p-Air1/2p-Mtr4p polyadenylation (TRAMP) complex before subsequent nuclear-exosome-mediated degradation. TRAMP facilitates pre-mRNA splicing (Kong et al., 2013).
- PAX5 is a lineage-specific transcription factor; recognizes the concensus recognition sequence GNCCANTGAAGCGTGAC, where N is any nucleotide. Involved in B-cell differentiation. Entry of common lymphoid progenitors into the B cell lineage depends on E2A, EBF1, and PAX5; activates B-cell specific genes and represses genes involved in other lineage commitments. Activates the surface cell receptor CD19 and represses FLT3. PAX5 physically interacts with the RAG1/RAG2 complex, and removes the inhibitory signal of the lysine-9-methylated histone H3, and induces V-to-DJ rearrangements. Genes repressed by PAX5 expression in early B cells are restored in their function in mature B cells and plasma cells, and PAX5 repressed (Fuxa et al., 2004; Johnson et al., 2004; Zhang et al., 2006; Cobaleda et al., 2007).
Gene name
MYC v-myc myelocytomatosis viral oncogene homolog (avian)
Location
8q24.21
Protein description
DNA binding protein. Binds DNA as a heterodimer with MAX. Involved in various cellular processes including cell growth, proliferation, cell adhesion, apoptosis, angiogenesis, and stem cell behaviour modulation.
Result of the Chromosomal Anomaly
Expression localisation
There was abundant MYC expression in all the cases studied.
Highly cited references
| Pubmed ID | Year | Title | Citations |
|---|---|---|---|
| 37450923 | 2024 | MYC Oncogene: A Druggable Target for Treating Cancers with Natural Products. | 590 |
| 35203395 | 2022 | Normal and Neoplastic Growth Suppression by the Extended Myc Network. | 410 |
| 36835628 | 2023 | The "Superoncogene" Myc at the Crossroad between Metabolism and Gene Expression in Glioblastoma Multiforme. | 330 |
| 36902175 | 2023 | When Just One Phosphate Is One Too Many: The Multifaceted Interplay between Myc and Kinases. | 264 |
| 30909496 | 2019 | MYC Oncogene Contributions to Release of Cell Cycle Brakes. | 243 |
| 36611833 | 2022 | Lessons from Using Genetically Engineered Mouse Models of MYC-Induced Lymphoma. | 234 |
| 33322239 | 2020 | The Molecular 'Myc-anisms' Behind Myc-Driven Tumorigenesis and the Relevant Myc-Directed Therapeutics. | 230 |
| 22464321 | 2012 | MYC on the path to cancer. | 229 |
| 34508258 | 2022 | The MYC oncogene - the grand orchestrator of cancer growth and immune evasion. | 227 |
| 26382145 | 2015 | MYC, Metabolism, and Cancer. | 223 |
| 28398229 | 2017 | Controlling the Master: Chromatin Dynamics at the MYC Promoter Integrate Developmental Signaling. | 217 |
| 30597997 | 2018 | Therapeutic Inhibition of Myc in Cancer. Structural Bases and Computer-Aided Drug Discovery Approaches. | 212 |
| 34978469 | 2022 | Target c-Myc to treat pancreatic cancer. | 206 |
| 37941901 | 2023 | MYC function and regulation in physiological perspective. | 191 |
| 36969025 | 2023 | Strategies to target the cancer driver MYC in tumor cells. | 186 |
| 33801599 | 2021 | Gene Transactivation and Transrepression in MYC-Driven Cancers. | 181 |
| 38390324 | 2024 | Targeting MYC at the intersection between cancer metabolism and oncoimmunology. | 180 |
| 30451365 | 2019 | Intricate crosstalk between MYC and non-coding RNAs regulates hallmarks of cancer. | 174 |
| 38957016 | 2024 | Immune evasion: An imperative and consequence of MYC deregulation. | 164 |
| 26416427 | 2015 | MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management. | 162 |
| 34942444 | 2022 | Therapeutic targeting of "undruggable" MYC. | 159 |
| 31832515 | 2019 | Writing and erasing MYC ubiquitination and SUMOylation. | 159 |
| 34658888 | 2021 | Targeting Myc Interacting Proteins as a Winding Path in Cancer Therapy. | 158 |
| 35741402 | 2022 | MTBP and MYC: A Dynamic Duo in Proliferation, Cancer, and Aging. | 156 |
| 28245597 | 2017 | MYC in Regulating Immunity: Metabolism and Beyond. | 142 |
| 25274755 | 2014 | Therapeutic strategies to inhibit MYC. | 138 |
| 36417849 | 2022 | MYC regulates a pan-cancer network of co-expressed oncogenic splicing factors. | 127 |
| 32071436 | 2020 | Target gene-independent functions of MYC oncoproteins. | 126 |
| 36734615 | 2023 | Demystifying the Druggability of the MYC Family of Oncogenes. | 122 |
| 33692331 | 2021 | Alternative approaches to target Myc for cancer treatment. | 121 |
| 34178666 | 2021 | Targeting the MYC Ubiquitination-Proteasome Degradation Pathway for Cancer Therapy. | 120 |
| 37457123 | 2023 | Targeting MYC-driven lymphoma: lessons learned and future directions. | 116 |
| 32160543 | 2020 | MYC Dysregulates Mitosis, Revealing Cancer Vulnerabilities. | 105 |
| 38302473 | 2024 | Nuclear to cytoplasmic transport is a druggable dependency in MYC-driven hepatocellular carcinoma. | 103 |
| 33092025 | 2020 | MYC in Brain Development and Cancer. | 99 |
| 29527331 | 2018 | Targeting oncogenic Myc as a strategy for cancer treatment. | 97 |
| 30470303 | 2018 | The MYC Enhancer-ome: Long-Range Transcriptional Regulation of MYC in Cancer. | 94 |
| 36765089 | 2023 | Loss of phosphatase CTDNEP1 potentiates aggressive medulloblastoma by triggering MYC amplification and genomic instability. | 93 |
| 18032916 | 2007 | Feedback regulation of c-Myc by ribosomal protein L11. | 88 |
| 35115371 | 2022 | MYC overexpression leads to increased chromatin interactions at super-enhancers and MYC binding sites. | 86 |
| 38565249 | 2024 | A germline point mutation in the MYC-FBW7 phosphodegron initiates hematopoietic malignancies. | 84 |
| 29173017 | 2020 | MYC leads the way. | 81 |
| 35244724 | 2022 | The MYC oncoprotein directly interacts with its chromatin cofactor PNUTS to recruit PP1 phosphatase. | 77 |
| 36930677 | 2023 | TXNIP loss expands Myc-dependent transcriptional programs by increasing Myc genomic binding. | 75 |
| 37105989 | 2023 | DNA polymerase POLD1 promotes proliferation and metastasis of bladder cancer by stabilizing MYC. | 68 |
| 32715994 | 2020 | Dissecting transcriptional amplification by MYC. | 68 |
| 31679823 | 2019 | Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy. | 67 |
| 36351945 | 2022 | Reversible Myc hypomorphism identifies a key Myc-dependency in early cancer evolution. | 66 |
| 25475704 | 2015 | Taming of the beast: shaping Myc-dependent amplification. | 65 |
| 37852796 | 2023 | MYC acetylated lysine residues drive oncogenic cell transformation and regulate select genetic programs for cell adhesion-independent growth and survival. | 64 |
| 24394940 | 2014 | c-MYC-miRNA circuitry: a central regulator of aggressive B-cell malignancies. | 63 |
| 31455158 | 2019 | Oncogenic MYC amplifies mitotic perturbations. | 61 |
| 27081479 | 2016 | Strategically targeting MYC in cancer. | 59 |
| 34911936 | 2021 | Androgen receptor and MYC equilibration centralizes on developmental super-enhancer. | 59 |
| 33298911 | 2020 | TRIB3 promotes MYC-associated lymphoma development through suppression of UBE3B-mediated MYC degradation. | 55 |
| 35217790 | 2022 | Prostate-specific oncogene OTUD6A promotes prostatic tumorigenesis via deubiquitinating and stabilizing c-Myc. | 53 |
| 39122009 | 2024 | SOX2 represses c-MYC transcription by altering the co-activator landscape of the c-MYC super-enhancer and promoter regions. | 53 |
| 33275307 | 2021 | Gold-Based Pharmacophore Inhibits Intracellular MYC Protein. | 52 |
| 20445224 | 2010 | Cdk2: a key regulator of the senescence control function of Myc. | 52 |
| 32482868 | 2020 | MYC protein stability is negatively regulated by BRD4. | 50 |
| 35296795 | 2022 | Deubiquitination of MYC by OTUB1 contributes to HK2 mediated glycolysis and breast tumorigenesis. | 50 |
| 27926480 | 2017 | Calcium-dependent binding of Myc to calmodulin. | 44 |
| 24857145 | 2014 | Taking on challenging targets: making MYC druggable. | 40 |
| 35167621 | 2022 | Cryptic MYC insertions in Burkitt lymphoma: New data and a review of the literature. | 39 |
| 32966806 | 2021 | Discovery of a Functional Covalent Ligand Targeting an Intrinsically Disordered Cysteine within MYC. | 37 |
| 38546691 | 2024 | MYC overexpression in natural killer cell lymphoma: prognostic and therapeutic implications. | 36 |
| 35962189 | 2022 | Myc inhibition tips the immune balance to promote antitumor immunity. | 36 |
| 38207206 | 2024 | MYC rearrangements in HIV-associated large B-cell lymphomas: EUROMYC, a European retrospective study. | 35 |
| 35438057 | 2022 | Ubiquitylation of unphosphorylated c-myc by novel E3 ligase SCF(Fbxl8). | 32 |
| 38184753 | 2024 | Non-IG::MYC in diffuse large B-cell lymphoma confers variable genomic configurations and MYC transactivation potential. | 26 |
| 26383167 | 2015 | The MYC-WDR5 Nexus and Cancer. | 24 |
| 33524794 | 2021 | MYC as a target for cancer treatment. | 0 |
| 24704206 | 2015 | Myc and cell cycle control. | 0 |
| 9558477 | 1998 | The many roles of c-Myc in apoptosis. | 0 |
| 1751543 | 1991 | c-myc oncoprotein function. | 0 |
| 8822795 | 1996 | Myc-mediated apoptosis. | 0 |
| 24933113 | 2015 | Myc and its interactors take shape. | 0 |
| 38583818 | 2024 | Exploring Myc puzzle: Insights into cancer, stem cell biology, and PPI networks. | 0 |
| 31068032 | 2019 | MYC modulators in cancer: a patent review. | 0 |
| 25564254 | 2015 | MYC-mediated synthetic lethality for treatment of hematological malignancies. | 0 |
| 25553514 | 2015 | MYC-mediated synthetic lethality for treating tumors. | 0 |
| 34019288 | 2021 | MYC Analysis in Cancer and Evolution. | 0 |
| 34019283 | 2021 | An "-omycs" Toolbox to Work with MYC. | 0 |
| 12628347 | 2003 | Transcriptional repression by Myc. | 0 |
| 29171017 | 2017 | Pathogenesis and therapeutic targeting of aberrant MYC expression in haematological cancers. | 0 |
| 32074595 | 2020 | The Spectrum of MYC Alterations in Diffuse Large B-Cell Lymphoma. | 0 |
| 3034933 | 1987 | Myc family of cellular oncogenes. | 0 |
| 24608428 | 2015 | Targeting RNA polymerase I to treat MYC-driven cancer. | 0 |
| 39468222 | 2025 | Transcriptional regulation by MYC: an emerging new model. | 0 |
| 23696362 | 2013 | Myc in stem cell behaviour: insights from Drosophila. | 0 |
| 24731854 | 2015 | The activities of MYC, MNT and the MAX-interactome in lymphocyte proliferation and oncogenesis. | 0 |
| 19806017 | 2009 | MYC, microRNAs and glutamine addiction in cancers. | 0 |
| 39306615 | 2024 | MYC upstream region orchestrates resistance to PI3K inhibitors in cancer cells through FOXO3a-mediated autophagic adaptation. | 0 |
| 11607812 | 2001 | Translocations involving c-myc and c-myc function. | 0 |
| 21704229 | 2011 | Proteolytic control of the oncoprotein transcription factor Myc. | 0 |
| 1363364 | 1992 | DNA binding by the Myc oncoproteins. | 0 |
| 20713526 | 2010 | Tipping the balance: Cdk2 enables Myc to suppress senescence. | 0 |
| 10579912 | 1999 | Function of the c-Myc oncogenic transcription factor. | 0 |
| 11684436 | 2001 | The interplay between Mad and Myc in proliferation and differentiation. | 0 |
| 12565816 | 2003 | Mechanisms of c-myc-mediated transcriptional repression of growth arrest genes. | 0 |
Article Bibliography
| Pubmed ID | Last Year | Title | Authors |
|---|---|---|---|
| 17230227 | 2007 | Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas. | Bertrand P et al |
| 18297523 | 2008 | C-MYC translocation in t(14;18) positive follicular lymphoma at presentation: An adverse prognostic indicator? | Christie L et al |
| 17440452 | 2007 | Pax5: the guardian of B cell identity and function. | Cobaleda C et al |
| 17074591 | 2006 | Translocation (14;18)(q32;q21) in acute lymphoblastic leukemia: a study of 12 cases and review of the literature. | D'Achille P et al |
| 12708908 | 2003 | Mature B-cell acute lymphoblastic leukemia with associated translocations (14;18)(q32;q21) and (8;9)(q24;p13). A Burkitt variant? | Dunphy CH et al |
| 15004008 | 2004 | Pax5 induces V-to-DJ rearrangements and locus contraction of the immunoglobulin heavy-chain gene. | Fuxa M et al |
| 7579360 | 1995 | Cytogenetic evolution patterns in non-Hodgkin's lymphoma. | Johansson B et al |
| 15258579 | 2004 | B cell-specific loss of histone 3 lysine 9 methylation in the V(H) locus depends on Pax5. | Johnson K et al |
| 19597184 | 2009 | Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. | Johnson NA et al |
| 19491398 | 2009 | A novel POK family transcription factor, ZBTB5, represses transcription of p21CIP1 gene. | Koh DI et al |
| 24097436 | 2014 | Cotranscriptional recruitment of yeast TRAMP complex to intronic sequences promotes optimal pre-mRNA splicing. | Kong KY et al |
| 18024371 | 2007 | The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. | Le Gouill S et al |
| 2506953 | 1989 | Four new recurring translocations in non-Hodgkin lymphoma. | Levine EG et al |
| 8324225 | 1993 | C-MYC translocations in de novo B-cell lineage acute leukemias with t(14;18)(cell lines Karpas 231 and 353). | Nacheva E et al |
| 21718139 | 2011 | De novo B lymphoblastic leukemia/lymphoma in an adult with t(14;18)(q32;q21) and c-MYC gene rearrangement involving 10p13. | Subramaniyam S et al |
| 16680144 | 2006 | Transcription factor Pax5 (BSAP) transactivates the RAG-mediated V(H)-to-DJ(H) rearrangement of immunoglobulin genes. | Zhang Z et al |
Citation
Jean-Loup Huret
t(8;9)(q24;p13) ?/MYC
Atlas Genet Cytogenet Oncol Haematol. 2013-10-01
Online version: http://atlasgeneticsoncology.org/haematological/2141/t(8
